AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27866695 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable risperidone
Number of subjects: 986
Study 27867088 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-EPI-VASO
Number of subjects: 0
Study 27867088 — intervention group
Group type: COMPARATOR
Intervention: 2D-SMS-VASO
Number of subjects: 0
Study 27867088 — intervention group
Group type: COMPARATOR
Intervention: GE-BOLD fMRI
Number of subjects: 0
Study 27868083 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation group (REHACOP)
Number of subjects: 111
Study 27868083 — intervention group
Group type: COMPARATOR
Intervention: Active control group (occupational activities)
Number of subjects: 111
Study 27868471 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin monotherapy
Number of subjects: 52
Study 27868471 — intervention group
Group type: EXPERIMENTAL
Intervention: CD30 expression quantitated by computer-assisted digital image analysis (cIHC)
Number of subjects: 52
Study 27869650 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic or pharmacologic disruption of mitochondrial respiration
Number of subjects: 0
Study 27869650 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment in LFS patients
Number of subjects: 0
Study 27869909 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokines (IL-6, IL-8, IL-10, IL-12, SFRP4) and miRNAs (miR-21, miR-24.1, miR-27a, miR-28-3p, miR-29b, miR-30d, miR-34a, miR-93, miR-126, miR-146a, miR-148, miR-150, miR-155, miR-223)
Number of subjects: 58
Study 27869909 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 58
Study 27870734 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative copeptin (≥9.6 pmol/L)
Number of subjects: 190
Study 27871260 — intervention group
Group type: EXPERIMENTAL
Intervention: First trimester weight at 4-10 weeks gestation
Number of subjects: 43
Study 27871260 — intervention group
Group type: EXPERIMENTAL
Intervention: First trimester weight at 12 weeks gestation
Number of subjects: 43
Study 27871260 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight participants at 4-10 weeks
Number of subjects: 43
Study 27871260 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight/obese participants at 4-10 weeks
Number of subjects: 43
Study 27871260 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight participants at 12 weeks
Number of subjects: 43
Study 27871260 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight/obese participants at 12 weeks
Number of subjects: 43
Study 27871301 — intervention group
Group type: EXPERIMENTAL
Intervention: Research suggestions from patients and patient organisations
Number of subjects: 24
Study 27871301 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding factors that cause disease manifestations
Number of subjects: 24
Study 27871301 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning more about the clinical and psychological/social impact of living with the disease
Number of subjects: 24
Study 27871301 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcomes of a transplant without eculizumab
Number of subjects: 24
Study 27871301 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-kidney damage in patients with aHUS
Number of subjects: 24
Study 27871301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing analysis of data collected in the Registry on patients with kidney transplants
Number of subjects: 24
Study 27871319 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP02 (irinotecan liposome injection) at 80 mg/m²
Number of subjects: 16
Study 27871319 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP02 (irinotecan liposome injection) in combination with 5-FU and LV
Number of subjects: 16
Study 27871675 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonists (GLP-1-RAs)
Number of subjects: 0
Study 27871854 — intervention group
Group type: EXPERIMENTAL
Intervention: Micra transcatheter pacemaker
Number of subjects: 42
Study 27872037 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based delivery of 6 evidence-based health promotion programs (sexual health, hearing loss, alcohol use, tobacco use, drug use, nutrition and physical activity)
Number of subjects: 191
Study 27872037 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based delivery of 6 evidence-based health promotion programs
Number of subjects: 191
Study 27872060 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib, dexamethasone, and rituximab (BDR)
Number of subjects: 59
Study 27872060 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib alone (1.3 mg/m2)
Number of subjects: 59
Study 27872070 — intervention group
Group type: EXPERIMENTAL
Intervention: Cipargamin 30 mg
Number of subjects: 25
Study 27872070 — intervention group
Group type: EXPERIMENTAL
Intervention: Cipargamin 20 mg
Number of subjects: 25
Study 27872070 — intervention group
Group type: EXPERIMENTAL
Intervention: Cipargamin 10 mg
Number of subjects: 25
Study 27872070 — intervention group
Group type: EXPERIMENTAL
Intervention: Cipargamin 15 mg
Number of subjects: 25
Study 27872070 — intervention group
Group type: EXPERIMENTAL
Intervention: Cipargamin (all doses)
Number of subjects: 25
Study 27872072 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 36
Study 27872115 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT) performed at 18-20 gestational weeks (early OGTT)
Number of subjects: 570
Study 27872115 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose tolerance test (OGTT) performed at 24-28 gestational weeks (regular OGTT)
Number of subjects: 570
Study 27872115 — intervention group
Group type: EXPERIMENTAL
Intervention: Early OGTT
Number of subjects: 570
Study 27872130 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib (GDC-0068), 200 mg daily or more
Number of subjects: 0
Study 27872130 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib (GDC-0068)
Number of subjects: 0
Study 27872236 — intervention group
Group type: EXPERIMENTAL
Intervention: RO6836191 (single doses)
Number of subjects: 0
Study 27872236 — intervention group
Group type: EXPERIMENTAL
Intervention: RO6836191 (repeat-dose toxicity studies)
Number of subjects: 0
Study 27872611 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Grain Oat Granola (WGO)
Number of subjects: 32
Study 27872611 — intervention group
Group type: COMPARATOR
Intervention: Non-Whole Grain (NWG) breakfast cereals
Number of subjects: 32
Study 27873237 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 0
Study 27873237 — intervention group
Group type: COMPARATOR
Intervention: Historical patients (control)
Number of subjects: 0
Study 27873291 — intervention group
Group type: EXPERIMENTAL
Intervention: High SPD (above the 85th percentile)
Number of subjects: 758
Study 27875056 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs (both OTC and prescribed)
Number of subjects: 2767
Study 27875056 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 2767
Study 27875368 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided radiofrequency neurotomy of the superior medial, superior lateral and inferior medial genicular nerves
Number of subjects: 25
Study 27875488 — intervention group
Group type: EXPERIMENTAL
Intervention: IV esomeprazole, infusion duration of 10 to 30 minutes
Number of subjects: 167
Study 27875488 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral esomeprazole, pediatric doses based on population pharmacokinetic modeling
Number of subjects: 167
Study 27875488 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-response analysis for intragastric pH
Number of subjects: 167
Study 27875488 — intervention group
Group type: COMPARATOR
Intervention: Mucosal healing assessed by endoscopy
Number of subjects: 167
Study 27875519 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin receptor expression measured on circulating tumour cells (CTCs) using CellSearch and immunohistochemistry on matched tissue samples.
Number of subjects: 0
Study 27875519 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometry analysis of SSTR expression.
Number of subjects: 0
Study 27875999 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial HBB training
Number of subjects: 835
Study 27875999 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-refresher training evaluation
Number of subjects: 835
Study 27876675 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib plus docetaxel (2.0 mg once daily, 75 mg/m2 docetaxel)
Number of subjects: 89
Study 27876675 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib plus pemetrexed
Number of subjects: 89
Study 27878356 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous triapine (48-96 mg/m) in combination with cisplatin chemotherapy
Number of subjects: 0
Study 27878356 — intervention group
Group type: COMPARATOR
Intervention: Intravenous triapine (48-96 mg/m)
Number of subjects: 0
Study 27878474 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of warfarin
Number of subjects: 150
Study 27878567 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib 150 mg daily for 9 days
Number of subjects: 24
Study 27878567 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg on days 1 and 10
Number of subjects: 24
Study 27878619 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated carbon applied locally into the rectum twice daily for 8 weeks
Number of subjects: 28
Study 27878892 — intervention group
Group type: EXPERIMENTAL
Intervention: SIGLEC9 polymorphisms (specifically the G allele of rs2075803 and rs2075803 G/rs2258983 A haplotype)
Number of subjects: 135
Study 27878892 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloid cell line expressing the Siglec-9 variant corresponding to GA haplotype
Number of subjects: 135
Study 27878892 — intervention group
Group type: EXPERIMENTAL
Intervention: SIGLEC9 rs2075803 G/rs2258983 A haplotype
Number of subjects: 135
Study 27878906 — intervention group
Group type: EXPERIMENTAL
Intervention: simeprevir 150 mg, daclatasvir 60 mg and sofosbuvir 400 mg, once daily for 12 weeks
Number of subjects: 40
Study 27879486 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir administered from week 28 of pregnancy until delivery
Number of subjects: 31
Study 27879486 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir plus serovaccination to newborns
Number of subjects: 31
Study 27879972 — intervention group
Group type: EXPERIMENTAL
Intervention: REGN2810 (anti-PD-1 monoclonal antibody)
Number of subjects: 2
Study 27881039 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine, cyclophosphamide, and lenalidomide (starting dose 2.5 mg, maximum tolerated dose 5 mg)
Number of subjects: 40
Study 27881039 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine, cyclophosphamide, and lenalidomide (FC regimen)
Number of subjects: 40
Study 27881132 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 μg
Number of subjects: 3345
Study 27881132 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 200 μg
Number of subjects: 3345
Study 27881132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3345
Study 27881360 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 800
Study 27881360 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 800
Study 27881568 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 myocardial infarction (T2MI)
Number of subjects: 1251
Study 27881568 — intervention group
Group type: EXPERIMENTAL
Intervention: T2MI
Number of subjects: 1251
Study 27881568 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident diagnosis of T2MI
Number of subjects: 1251
Study 27881569 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-duration oral betrixaban (80 mg once daily for 35-42 days)
Number of subjects: 7513
Study 27881569 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose subcutaneous enoxaparin (40 mg once daily for 10±4 days)
Number of subjects: 7513
Study 27881690 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use food (RUF) protocols with Plumpy Nut and Plumpy Sup supplied every 2 weeks, prescribed by weight
Number of subjects: 43
Study 27881690 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use food (RUF) protocols
Number of subjects: 43
Study 27882104 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell (MSC) infusion derived from human umbilical cord
Number of subjects: 34
Study 27882418 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) guidelines compliance
Number of subjects: 168
Study 27882418 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative discharge criteria fulfillment
Number of subjects: 168
Study 27882418 — intervention group
Group type: COMPARATOR
Intervention: Postoperative complications
Number of subjects: 168
Study 27882418 — intervention group
Group type: COMPARATOR
Intervention: Length of hospitalization
Number of subjects: 168
Study 27882418 — intervention group
Group type: COMPARATOR
Intervention: Readmission rate
Number of subjects: 168
Study 27883002 — intervention group
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Number of subjects: 0
Study 27883166 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rapamycin (0.5mg, 1.0mg, 2mg daily for 12 weeks)
Number of subjects: 13
Study 27883239 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (individualized dosing)
Number of subjects: 23
Study 27883239 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (elevated dose)
Number of subjects: 23
Study 27883239 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (normal dose)
Number of subjects: 23
Study 27883297 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (maintenance dose)
Number of subjects: 93
Study 27884107 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery under general anesthesia
Number of subjects: 70
Study 27884107 — intervention group
Group type: COMPARATOR
Intervention: Matched nonsurgical controls
Number of subjects: 70
Study 27884134 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a plus ribavirin
Number of subjects: 81
Study 27884134 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alpha-2b plus ribavirin
Number of subjects: 81
Study 27884134 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 81
Study 27884137 — intervention group
Group type: COMPARATOR
Intervention: Preventive sick leave intervention by the general practitioner (GP) using the Work Stress Questionnaire (WSQ), GP training in the use of WSQ, GP feedback at consultation, and finding suitable preventive measures.
Number of subjects: 0
Study 27884137 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group).
Number of subjects: 0
Study 27884140 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (on day 1, every 3 weeks) and cetuximab (on day 1, weekly), in combination with oral valproic acid (VPA) given daily from day -14 with a target serum level of 50-100 μg/ml.
Number of subjects: 60
Study 27884140 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and cetuximab with valproic acid (VPA)
Number of subjects: 60
Study 27884157 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiScanner® CGM device
Number of subjects: 88
Study 27884157 — intervention group
Group type: COMPARATOR
Intervention: Reference method (standard reference method for BG measurement)
Number of subjects: 88
Study 27884211 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative plasma glutamine level
Number of subjects: 90
Study 27884211 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative plasma glutamine level
Number of subjects: 90
Study 27884211 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative plasma glutamine levels
Number of subjects: 90
Study 27884313 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal BMI (18.5-22.9)
Number of subjects: 1078
Study 27884313 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight (23.0-27.4)
Number of subjects: 1078
Study 27884313 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese (27.5 and over)
Number of subjects: 1078
Study 27884766 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2256294 (10 μM)
Number of subjects: 23
Study 27884766 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2256294 (18 mg)
Number of subjects: 23
Study 27884766 — intervention group
Group type: COMPARATOR
Intervention: Bradykinin
Number of subjects: 23
Study 27884766 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 23
Study 27884766 — intervention group
Group type: COMPARATOR
Intervention: EET/dihydroxyepoxyeicosatrienoic acid ratio
Number of subjects: 23
Study 27884941 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical performance tests and sociodemographic surveys
Number of subjects: 480
Study 27884941 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate prediction models
Number of subjects: 480
Study 27884941 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of a multivariate model
Number of subjects: 480
Study 27885499 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 8 mg
Number of subjects: 61
Study 27885499 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg
Number of subjects: 61
Study 27885830 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 0
Study 27886569 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 240
Study 27887595 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship program of Chinese MOH
Number of subjects: 978
Study 27887632 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib (antiangiogenic drug)
Number of subjects: 0
Study 27887644 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (cART)
Number of subjects: 1500
Study 27887644 — intervention group
Group type: COMPARATOR
Intervention: Uninfected controls from the Copenhagen General Population Study (CGPS)
Number of subjects: 1500
Study 27887654 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting the 24-h movement recommendations (all three behaviors)
Number of subjects: 6128
Study 27887654 — intervention group
Group type: EXPERIMENTAL
Intervention: Including the MVPA recommendation in the analysis
Number of subjects: 6128
Study 27887660 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-infusion of haplo-identical donor-derived CD19-directed CAR-T cells and mobilized peripheral blood stem cells (PBSC)
Number of subjects: 1
Study 27887660 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-infusion of haplo-identical donor-derived CD19-directed CAR-T cells and mobilized PBSC
Number of subjects: 1
Study 27887718 — intervention group
Group type: EXPERIMENTAL
Intervention: Trak Male Fertility Testing System
Number of subjects: 239
Study 27887774 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 0
Study 27888172 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent inactive disease (t2)
Number of subjects: 370
Study 27888172 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing from very high disease activity to inactive disease (t3)
Number of subjects: 370
Study 27888172 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent high disease activity (t4)
Number of subjects: 370
Study 27888172 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent very high disease activity (t5)
Number of subjects: 370
Study 27888609 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Number of subjects: 169
Study 27888609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 27888649 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon sinus dilation
Number of subjects: 50
Study 27888762 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine omega-3 eicosapentaenoic acid (EPA)
Number of subjects: 100
Study 27889300 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily combined with methotrexate
Number of subjects: 2136
Study 27889300 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 2136
Study 27889300 — intervention group
Group type: COMPARATOR
Intervention: Other active treatments
Number of subjects: 2136
Study 27890073 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice per day
Number of subjects: 191
Study 27890073 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 600 mg once per day
Number of subjects: 191
Study 27890073 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice per day (excluding crossover responses)
Number of subjects: 191
Study 27890073 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 600 mg once per day (excluding crossover responses)
Number of subjects: 191
Study 27890471 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat (0.5-2.5 mg TID) during a 10-week titration phase and a 14-week maintenance phase
Number of subjects: 0
Study 27890471 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat (0.5-2.5 mg TID)
Number of subjects: 0
Study 27890526 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel eluting balloon (PEB) angioplasty
Number of subjects: 53
Study 27890712 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative CT measures of BA ratio
Number of subjects: 42
Study 27890712 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative CT measures of wall thickness (WT)
Number of subjects: 42
Study 27890712 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative CT measures of wall area percent (WA%)
Number of subjects: 42
Study 27890712 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchiectatic airways
Number of subjects: 42
Study 27890936 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment cessation
Number of subjects: 100
Study 27890936 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional characterization of NK and T cells
Number of subjects: 100
Study 27890936 — intervention group
Group type: COMPARATOR
Intervention: Comparison with T and B cells
Number of subjects: 100
Study 27891160 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment
Number of subjects: 288
Study 27891190 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-free DNA promoter hypermethylation
Number of subjects: 0
Study 27891190 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation-specific PCR of a 28 gene panel
Number of subjects: 0